U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula CO3.2Na.10H2O
Molecular Weight 286.1412
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SODIUM CARBONATE DECAHYDRATE

SMILES

O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].[O-]C([O-])=O

InChI

InChIKey=XYQRXRFVKUPBQN-UHFFFAOYSA-L
InChI=1S/CH2O3.2Na.10H2O/c2-1(3)4;;;;;;;;;;;;/h(H2,2,3,4);;;10*1H2/q;2*+1;;;;;;;;;;/p-2

HIDE SMILES / InChI

Molecular Formula CH2O3
Molecular Weight 62.0248
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula H2O
Molecular Weight 18.0153
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula Na
Molecular Weight 22.9898
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/26617001 | https://www.ncbi.nlm.nih.gov/pubmed/3449184 | https://www.ncbi.nlm.nih.gov/pubmed/3449184 | https://www.ncbi.nlm.nih.gov/pubmed/16864561

Diammonium carbonate is a salt with the chemical formula (NH4)2CO3. Since it readily degrades to gaseous ammonia and carbon dioxide upon heating, it is used as a leavening agent and also as smelling salt. Ammonium carbonate may be used as a leavening agent in traditional recipes, particularly those from northern Europe and Scandinavia (e.g. Speculoos, Tunnbröd or Lebkuchen). It also serves as an acidity regulator and has the E number E503. Ammonium carbonate is the main component of smelling salts, although the commercial scale of their production is small. Buckley's cough syrup from Canada today uses ammonium carbonate as an active ingredient intended to help relieve symptoms of bronchitis. Ammonium carbonate is also used as an emetic.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
85.0 mM [Ki]
12.0 mM [Ki]
95.0 mM [Ki]
0.27 mM [Ki]
0.086 mM [Ki]
0.8 mM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
SODIUM BICARBONATE

Approved Use

INDICATIONS AND USAGE. Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of hemoglobin and its breakdown products. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate.

Launch Date

2005
Curative
SODIUM BICARBONATE

Approved Use

INDICATIONS AND USAGE. Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of hemoglobin and its breakdown products. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate.

Launch Date

2005
Primary
SODIUM BICARBONATE

Approved Use

INDICATIONS AND USAGE. Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of hemoglobin and its breakdown products. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate.

Launch Date

2005
PubMed

PubMed

TitleDatePubMed
Role of NHE isoforms in mediating bicarbonate reabsorption along the nephron.
2001 Dec
Modification of a single tryptophan residue in human Cu,Zn-superoxide dismutase by peroxynitrite in the presence of bicarbonate.
2001 Jul 9
Anion exchanger isoform 2 operates in parallel with Na(+)/H(+) exchanger isoform 1 during regulatory volume decrease of human cervical cancer cells.
2002 Feb 13
[HCO3-]-regulated expression and activity of soluble adenylyl cyclase in corneal endothelial and Calu-3 cells.
2004 Apr 29
Cystic fibrosis gene mutation reduces epithelial cell acidification and injury in acid-perfused mouse duodenum.
2004 Oct
Novel regulation of cystic fibrosis transmembrane conductance regulator (CFTR) channel gating by external chloride.
2004 Oct 1
Effect of bicarbonate on iron-mediated oxidation of low-density lipoprotein.
2005 Jul 26
ZIP8, member of the solute-carrier-39 (SLC39) metal-transporter family: characterization of transporter properties.
2006 Jul
DNA cleavage mediated by copper superoxide dismutase via two pathways.
2007 Feb
Does glucose infusion exacerbate metformin-associated lactate acidosis? A case report.
2009 Jul
Patents

Sample Use Guides

In cardiac arrest, a rapid intravenous dose of one to two 50 mL syringes (44.6 to 100 mEq) may be given initially and continued at a rate of 50 mL (44.6 to 50 mEq) every 5 to 10 minutes if necessary (as indicated by arterial pH and blood gas monitoring) to reverse the acidosis. Caution should be observed in emergencies where very rapid infusion of large quantities of bicarbonate is indicated. Bicarbonate solutions are hypertonic and may produce an undesirable rise in plasma sodium concentration in the process of correcting the metabolic acidosis. In cardiac arrest, however, the risks from acidosis exceed those of hypernatremia. In less urgent forms of metabolic acidosis. Sodium Bicarbonate Injection, USP may be added to other intravenous fluids. The amount of bicarbonate to be given to older children and adults over a four-to- eight-hour period is approximately 2 to 5 mEq/kg of body weight - depending upon the severity of the acidosis as judged by the lowering of total CO2 content blood pH and clinical condition of the patient In metabolic acidosis associated with shock, therapy should be monitored by measuring blood gases, plasma osmolar'rty, arterial blood lactate, hemodynamics and cardiac rhythm. Bicarbonate therapy should always be planned in a stepwise fashion since the degree of response from a given dose is not precisely predictable. Initially an infusion of 2 to 5 mEq/kg body weight over a period of 4 to 8 hours will produce a measurable improvement in the abnormal acid- base status of the blood. The next step of therapy is dependent upon the clinical response of the patient. If severe symptoms have abated, then the frequency of administration and the size of the dose may be reduced.
Route of Administration: Intravenous
A. thaliana var. Landsberg erecta (LER) suspension cells were treated with NaHCO3 at a final concentration of 1, 3, or 10 mM. For controls, NaNO3 (NO3 − is a macronutrient in MS media) was added in same concentration to nullify the effect of Na+ during the treatment. Furthermore, as HCO3 − induced significant pH changes of the MS media (pH 5.8), we added 50 mM (for 1 mM and 3 mM HCO3 −) and 100 mM (for 10 mM HCO3 −) MES buffer (pH 5.8) to the MS media, and the pH-stabilized MS media were used for both control and HCO3− treatments. In addition, the buffered MS media were sonicated to remove atmospheric gases prior to addition of HCO3−. Cells were incubated at 25 °C for 0, 5, 15, 30, 60, and 120 min on a shaker, and four replicates (n = 4) were generated for each data point after treatment with HCO3 − (treatment) and control. After treatment, 100 ml cells at a concentration of 3 x 10^6 ml−1 were filtered using filter paper mounted on funnels, quickly blotted dry using Kim wipes and immediately snap-frozen in liquid nitrogen and stored in a − 80 °C freezer until metabolite extraction.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:58:35 GMT 2023
Edited
by admin
on Fri Dec 15 15:58:35 GMT 2023
Record UNII
LS505BG22I
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SODIUM CARBONATE DECAHYDRATE
EP   II   MART.   MI  
Systematic Name English
NEVITE
Common Name English
SODIUM CARBONATE DECAHYDRATE [MI]
Common Name English
SODIUM CARBONATE HYDRATE
JAN  
Systematic Name English
SODIUM CARBONATE DECAHYDRATE [II]
Common Name English
SODIUM CARBONATE HYDRATE [JAN]
Common Name English
SODIUM CARBONATE DECAHYDRATE [MART.]
Common Name English
WASHING SODA
Common Name English
SODIUM CARBONATE DECAHYDRATE [EP MONOGRAPH]
Common Name English
SODIUM CARBONATE DECAHYDRATE [EP IMPURITY]
Common Name English
NATRON
Common Name English
SAL SODA
Common Name English
NATRITE
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C29730
Created by admin on Fri Dec 15 15:58:35 GMT 2023 , Edited by admin on Fri Dec 15 15:58:35 GMT 2023
Code System Code Type Description
SMS_ID
100000079334
Created by admin on Fri Dec 15 15:58:35 GMT 2023 , Edited by admin on Fri Dec 15 15:58:35 GMT 2023
PRIMARY
FDA UNII
LS505BG22I
Created by admin on Fri Dec 15 15:58:35 GMT 2023 , Edited by admin on Fri Dec 15 15:58:35 GMT 2023
PRIMARY
MERCK INDEX
m10001
Created by admin on Fri Dec 15 15:58:35 GMT 2023 , Edited by admin on Fri Dec 15 15:58:35 GMT 2023
PRIMARY Merck Index
DAILYMED
LS505BG22I
Created by admin on Fri Dec 15 15:58:35 GMT 2023 , Edited by admin on Fri Dec 15 15:58:35 GMT 2023
PRIMARY
RXCUI
1362143
Created by admin on Fri Dec 15 15:58:35 GMT 2023 , Edited by admin on Fri Dec 15 15:58:35 GMT 2023
PRIMARY RxNorm
PUBCHEM
151402
Created by admin on Fri Dec 15 15:58:35 GMT 2023 , Edited by admin on Fri Dec 15 15:58:35 GMT 2023
PRIMARY
CAS
6132-02-1
Created by admin on Fri Dec 15 15:58:35 GMT 2023 , Edited by admin on Fri Dec 15 15:58:35 GMT 2023
PRIMARY
NCI_THESAURUS
C81106
Created by admin on Fri Dec 15 15:58:35 GMT 2023 , Edited by admin on Fri Dec 15 15:58:35 GMT 2023
PRIMARY
EVMPD
SUB12281MIG
Created by admin on Fri Dec 15 15:58:35 GMT 2023 , Edited by admin on Fri Dec 15 15:58:35 GMT 2023
PRIMARY
EPA CompTox
DTXSID2052285
Created by admin on Fri Dec 15 15:58:35 GMT 2023 , Edited by admin on Fri Dec 15 15:58:35 GMT 2023
PRIMARY
MESH
C005686
Created by admin on Fri Dec 15 15:58:35 GMT 2023 , Edited by admin on Fri Dec 15 15:58:35 GMT 2023
PRIMARY
Related Record Type Details
ANHYDROUS->SOLVATE